Reaction rate in cats vaccinated with a new controlled-titer feline panleukopenia-rhinotracheitis-calicivirus-Chlamydia psittaci vaccine.
The safety profile of a new controlled-titer feline panleukopenia-rhinotracheitis-calicivirus-Chlamydia psittaci vaccine was compared to that of a currently-marketed vaccine. Of particular interest were delayed reactions (previously unreported in the literature in felines) occurring 7 to 21 days after vaccination, and the effect of concurrent vaccinations and cat age on the delayed reaction rate. Nineteen hundred twenty-four doses of the new vaccine and 364 doses of the comparison vaccine were administered in 42 participating veterinary practices. The postvaccination evaluation period was 21 days. Reactions (anaphylaxis, short- and long-term lethargy, inappetence, pain, upper respiratory inflammation, delayed fever, anorexia, and miscellaneous events) were reported in 3.33% of cats receiving the controlled-titer vaccine and in 3.02% of cats receiving the comparison vaccine. The difference was not statistically significant (P = 0.45). Reaction rate of the controlled-titer vaccine and that of the vaccine currently accepted by veterinarians appear to be equivalent.
Starr
R M
RM
SmithKline Beecham Animal Health, West Chester, PA 19380.
D000367:Age Factors; D000707:Anaphylaxis / Q000139:chemically induced / Q000662:veterinary; D000818:Animals; D001428:Bacterial Vaccines / Q000009:adverse effects* / Q000276:immunology; D017250:Caliciviridae Infections / Q000517:prevention & control / Q000662:veterinary; D017927:Calicivirus, Feline / Q000276:immunology*; D002371:Cat Diseases / Q000517:prevention & control; D002415:Cats; D002691:Chlamydophila psittaci / Q000276:immunology*; D005254:Feline Panleukopenia / Q000517:prevention & control; D028301:Feline Panleukopenia Virus / Q000276:immunology*; D005260:Female; D006564:Herpesviridae / Q000276:immunology*; D006566:Herpesviridae Infections / Q000517:prevention & control / Q000662:veterinary; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000662:veterinary; D008297:Male; D009956:Psittacosis / Q000517:prevention & control / Q000662:veterinary; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects* / Q000276:immunology
D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D014765:Viral Vaccines